acolbifene hydrochloride

DRUG2 trials

Sponsors

University of Kansas Medical Center, National Cancer Institute (NCI)

Conditions

Breast Atypical HyperplasiaBreast CancerBreast CarcinomaBreast Ductal Carcinoma In SituBreast Lobular Carcinoma In Situ

Phase 2

Acolbifene in Preventing Cancer in Premenopausal Women at High Risk of Breast Cancer

CompletedNCT00853996

University of Kansas Medical CenterBreast Cancer

Start: 2009-02-28End: 2010-12-31Updated: 2018-01-17

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

RecruitingNCT05941520

National Cancer Institute (NCI)Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ +1

Start: 2024-08-23End: 2028-09-01Target: 80Updated: 2026-04-06

Related Papers

Acolbifene vs tamoxifen for breast cancer prevention in premenopausal women at high risk for breast cancer.

Journal of Clinical Oncology2025-05-28